Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Procainamide

  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Procainamide is almost completely absorbed after oral administration and peak plasma concentrations are generally reached within 1 to 2 hours. Upon intravenous administration there is a rapid initial distribution phase, which is completed after about 30 minutes. The pharmacokinetics can be described by a 2-compartment open model. The plasma half-life during the β-phase averdges 3 hours. The apparent volume of distribution is about 2L/ kg body weight. At therapeutic plasma levels about 15 % is bound to plasma proteins.

Approximately 50% of administered procainamide is eliminated as unchanged drug via the kidneys. N-Acetylprocainamide is the main metabolite and is pharmacologically active, with a recovery in urine of about 15% (range 7 to 34% in healthy subjects). The acetylation of procainamide seems to be under the same monogenic control as that of isoniazid. At least 2 more metabolites have been found but are not yet identified. The renal clearance of procainamide ranges from 179 to 660ml/ min. Glomerular filtration and active tubular secretion seem to be the most important mechanisms.

In patients with low-output cardiac failure and / for renal impairment, the absorption, distribution and elimination of the drug may be significantly altered. Determination of plasma levels is of particular value in these cases and will contribute to more safe and effective therapy in the majority of patients. As N-acetylprocainamide seems to have pharmacological effects comparable with those of procainamide, both agents should be monitored simultaneously in order to optimise therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Arstila, M.; Katila, M.; Sundqvist, H.; Anttila, M.; Pere. E. and Tikkanen, R.: Dosage, plasma concentration and antiarrhythmic effect of procainamide in sustained-release tablets. Acta Medica Scandinavica 195: 217–222 (1974).

    Article  PubMed  CAS  Google Scholar 

  • Atkinson. A.J.,Jr.; Krumlovsky, FA.; Huang, C.M. and del Greco, F.: Hemodialysis for severe procainamide toxicity: Clinical and pharmacokinetic observations. Clinical Pharmacology and Therapeutics 20: 585–592 (1976).

    PubMed  Google Scholar 

  • Atkinson, A.J.,Jr.; Lee, W.-K.; Quinn, M.L.; Kushner, W.; Nevin, M.J. and Strong, J.M.: Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions. Clinical Pharmacology and Therapeutics 21: 575–587 (1977).

    PubMed  Google Scholar 

  • Atkinson, A.J.,Jr.; Parker, M. and Strong, J.: Rapid gas chromatographic measurement of plasma procainamide concentration. Clinical Chemistry 18: 643–646 (1972).

    PubMed  CAS  Google Scholar 

  • Benowitz, N.L. and Meister, W.: Pharmacokinetics in patients with cardiac failure. Clinical Pharmacokinetics 1: 389–405 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Breckenridge, A.: Pathophysiological factors influencing drug kinetics. In: Biological and Pharmaceutical Aspects of Pharmacokinetics and Therapeutics. Acta Pharmacologica et Toxicologica 29 (Suppl. 3): 225–232 (1971).

    PubMed  CAS  Google Scholar 

  • Campbell, W.; Tilstone, W.J.; Lawson, D.H.; Hutton, I. and Lawrie, T.D.V.: Acetylator phenotype and the clinical pharmacology of slow-release procainamide. British Journal of Clinical Pharmacology 3: 1023–1026 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Collste, P. and Karlsson, E.: Arrhythmia prophylaxis with procaine amide: Plasma concentrations in relation to dose. Acta Medica Scandinavica 194: 405–411 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Davies, D.M.; Beedie, M.A. and Rawlins, M.D.: Antinuclear antibodies during procainamide treatment and drug acetylation. British Medical Journal 3: 682–684 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Dreyfuss, J.; Bigger. J.T.H.,Jr.; Cohen, A.J. and Schreiber, E.C.: Metabolism of procainamide in rhesus monkey and man. Clinical Pharmacology and Therapeutics 13: 366–371 (1972).

    PubMed  CAS  Google Scholar 

  • Elson. J.; Strong, J.M.; Lee, W.-K. and Atkinson, A.J.,Jr.: Antiarrhythmic potency of N-acetylprocainamide. Clinical Pharmacology and Therapeutics 17: 134–140 (1975).

    PubMed  CAS  Google Scholar 

  • Fremstad, D.; Dahl, S.; Jacobsen, S.; Lunde, P.K.M.; Nadland, K.J.; Marthinsen, A. Aasness; Waaler, T. and Landmark. K.H.: A new sustained-release tablet formulation of procainamide. European Journal of Clinical Pharmacology 6: 251–255 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Frislid, K.; Bredesen, J.E. and Lunde, P.K.M.: Fluorometric or gas liquid chromatographic determination of procainamide? Clinical Chemistry 21: 1180–1181 (1975).

    PubMed  CAS  Google Scholar 

  • Frislid, K.; Berg, M.: Hansteen, V. and Lunde, P.K.M.: Comparison of the acetylation of procainamide and sulfadimidine in man. European Journal of Clinical Pharmacology 9: 433–438 (1976).

    Article  CAS  Google Scholar 

  • Galeazzi, R.L.; Sheiner, L.B.; Lockwood, T. and Benet. L.Z.: The renal elimination of procainamide. Clinical Pharmacology and Therapeutics 19: 55–62 (1976).

    PubMed  CAS  Google Scholar 

  • Gey, G.O.; Levy, R.H.; Fisher, L.; Pettet, G. and Bruce, R.A.: Plasma concentration of procainamide and prevalence of exertional arrhythmias. Annals of Internal Medicine 80: 718–722 (1974).

    PubMed  CAS  Google Scholar 

  • Giardina, E.-G.V.; Dreyfuss, J.; Bigger, J.T.,Jr.; Shaw, J.M. and Schreiber, E.C: Metabolism of procainamide in normal and cardiac subjects. Clinical Pharmacology and Therapeutics 19: 339–351 (1976).

    PubMed  CAS  Google Scholar 

  • Giardina, E.-G.V.; Heissenbuttel, R.H. and Bigger, J.T.,Jr.: Intermittant intravenous procainamide to treat ventricular arrhythmias; Correlation of plasma concentration with effect on arrhythmia, electrocardiogram and blood pressure. Annals of Internal Medicine 78: 183–193 (1973).

    PubMed  CAS  Google Scholar 

  • Giardina, E.-G.V.; Stein, R.M. and Bigger, J.T.: The relationship between the metabolism of procainamide and sulphamethazine. Circulation 55: 388–393 (1977).

    Article  CAS  Google Scholar 

  • Gibson. T.P.; Lowenthal, D.T.; Nelson, H.A. and Briggs, W.A.: Elimination of procainamide in end stage renal failure. Clinical Pharmacology and Therapeutics 17: 321–329 (1975a).

    PubMed  CAS  Google Scholar 

  • Gibson, T.P.; Matusik, J.; Matusik, E.: Nelson, H.A.; Wilkinson, J. and Briggs, W.A.: Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype. Clinical Pharmacology and Therapeutics 17: 395–399 (1975b).

    PubMed  CAS  Google Scholar 

  • Graffner. C.; Jansson, R.-M.; Lagerstrom, P.-O. and Persson, B.-A.: Disposition of procainamide and its N-acetylated metabolite after acute IV infusion in man determined by highspeed liquid chromatography. European Journal of Drug Metabolism and Pharmacokinetics 1: 29–36 (1977).

    Article  Google Scholar 

  • Graffner, C.; Johnsson, G. and Sjogren, J.: Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets. Clinical Pharmacology and Therapeutics 17: 414–423 (1975).

    PubMed  CAS  Google Scholar 

  • Hansteen, V.; Landmark, K.H.; Fremstad, D.; Dahl, S.G.; Jacobsen, S.; Marthinsen, A. Aasness; Waaler, T.; Frislid, K. and Lunde, P.K.M.: Maintenance therapy with a new retard tablet preparation of procainamide. American Heart Journal 92: 47–56 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Henningsen, N.C.; Cederberg, A.; Hansson, A. and Johansson, B.W.: Effects of long-term treatment with procaine amide. Acta Medica Scandinavica 198: 475–482 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Hurwitz, A.: Antacid therapy and drug kinetics. Clinical Pharmacokinetics 2: 269–280 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Karlsson, E.: Plasma levels of procaine amide after administration of conventional and sustained-release tablets. European Journal of Clinical Pharmacology 6: 245–250 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Karlsson, E.; Collste, P. and Rawlins, M.D.: Plasma levels of lidocaine during combined treatment with phenytoin and procainamide. European Journal of Clinical Pharmacology 7: 455–459 (1974a).

    Article  PubMed  CAS  Google Scholar 

  • Karlsson, E. and Molin, L.: Polymorphic acetylation of procaine amide in healthy subjects. Acta Medica Scandinavica 197: 299–302 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Karlsson, E.; Molin, L.; Norlander, B., and Sjoqvist, F.: Acetylation of procaine amide in man studied with a new gas chromatographic method. British Journal of Clinical Pharmacology 1: 467–475 (1974b).

    Article  PubMed  CAS  Google Scholar 

  • Karlsson, E. and Sonnhag, C.: Comparative evaluation of procainamide and its main metabolite, N-acetylprocainamide, in the acute treatment of ventricular arrhythmias. British Journal of Clinical Pharmacology 4: 632 (1977).

    Article  Google Scholar 

  • Koch-Weser, J.: Pharmacokinetics of procainamide in man; in Vesell (Ed) Drug Metabolism in Man. Annals of the New York Academy of Sciences 179: 370–382 (1971).

    Article  PubMed  CAS  Google Scholar 

  • Koch-Weser, J.: Serum procainamide levels as therapeutic guides. Clinical Pharmacokinetics 2: 389–402 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Koch-Weser, J. and Klein, S.W.: Procainamide dosage schedules, plasma concentrations and clinical effects. Journal of the American Medical Association 215: 1454–1460 (1971).

    Article  PubMed  CAS  Google Scholar 

  • Koch-Weser, J.; Klein, S.W.; Foo-Canto, L.L.; Kastor, J.A. and Descantis, R.W.: Antiarrhythmic prophylaxis with procaine amide in acute myocardial infarction. New England Journal of Medicine 281: 1253–1260 (1969).

    Article  PubMed  CAS  Google Scholar 

  • Kutt, H.: Dilantin metabolism in man: in Vesell (Ed) Drug Metabolism in Man. Annals of the New York Academy of Sciences 179: 704–722 (1971).

    Article  CAS  Google Scholar 

  • Kutt, H. and McDowell, F.: Management of epilepsy with diphenylhydantoin sodium. Journal of the American Medical Association 203: 167–170 (1968).

    Article  Google Scholar 

  • Lee, W.-K.; Strong, J.M.; Kehoe, R.F.; Dutcher, J.S. and Atkinson, A.J.,Jr.: Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions. Clinical Pharmacology and Therapeutics 19: 508–514 (1976).

    PubMed  CAS  Google Scholar 

  • Lunde, P.K.M.; Frislid, K. and Hansteen, V.: Disease and acetylation polymorphism. Clinical Pharmacokinetics 2: 182–197 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Mark, L.C.; Kayden. H.J.; Steele, J.M.; Cooper, J.R.; Berlin, I.; Rowenstine, E.A. and Brodie, B.B.: The physiological disposition and cardiac effects of procainamide. Journal of Pharmacological and Experimental Therapeutics 102: 5–15 (1951).

    CAS  Google Scholar 

  • Meyer, W.; Kaye, C.M., and Turner, P.: A study of the influence of pH on the buccal absorption and the renal excretion of procainamide. European Journal of Clinical Pharmacology. 7: 287–289 (1974).

    Article  PubMed  CAS  Google Scholar 

  • Reidenberg, M.M.; Drayer, D.E.; Levy, M. and Warner, H.: Polymorphic acetylation of procainamide in man. Clinical Pharmacology and Therapeutics 17: 722–730 (1975).

    PubMed  CAS  Google Scholar 

  • Remmer, H.: Induction of drug metabolizing enzyme systems in the liver. European Journal of Clinical Pharmacology 5: 116–136 (1972).

    Article  CAS  Google Scholar 

  • Rowland, M.; Benet, L.Z. and Graham, C.G.: Clearance concepts in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1: 123–136 (1973).

    PubMed  CAS  Google Scholar 

  • Shaw, T.R.D.; Kumana, C.R.; Kaye, C.M.; Padgham. C.; Kaspi, T. and Hamer, J.: Procainamide absorption studies to test the feasibility of using a sustained-release preparation. British Journal of Clinical Pharmacology 2: 515–519 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Sonnhag. C. and Karlsson, E.: Acetylator phenotype and lupus erythematosus-like syndrome in patients on long-term procainamide therapy. In preparation (1977).

  • du Souich, P. and Erill, S.: Metabolism of procaine and procainamide in patients with hepatic disease. Clinical Pharmacology and Therapeutics 19: 116 (1976).

    Google Scholar 

  • Strong, J.M.; Dutcher, J.S.; Lee. W.-K. and Atkinson. A.J.,Jr.: Pharmacokinetics in man of the N-acetylated metabolite of procainamide. Journal of Pharmacokinetics and Biopharmaceutics 3: 223–235 (1975).

    PubMed  CAS  Google Scholar 

  • Weily, H.S. and Genton, E.: Pharmacokinetics of procainamide. Archives of Internal Medicine 130: 366–369 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Weliky, I. and Neiss, E.S.: Absorption of procainamide from the human intestine. Clinical Pharmacology and Therapeutics 17: 248 (1975).

    Google Scholar 

  • Woosley, R.L.; Nies, A.S.; Drayer, D.E.; Reidenberg, M. and Oates, J.A.: Acetylator phenotype as a factor in procainamideinduced lupus. Clinical Research 25: 279A (1977).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Cardiology, Linkoping University, Linkoping, S-581 85, Sweden

    Erling Karlsson

Authors
  1. Erling Karlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karlsson, E. Clinical Pharmacokinetics of Procainamide. Clin Pharmacokinet 3, 97–107 (1978). https://doi.org/10.2165/00003088-197803020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-197803020-00001

Keywords

Search

Navigation